cabotegravir/recombinant human hyaluronidase PH20 (CAB/rHuPH20)
/ GSK, ViiV Healthcare
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
December 21, 2025
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=214 | Recruiting | Sponsor: ViiV Healthcare | Trial completion date: Nov 2027 ➔ Jun 2027 | Trial primary completion date: Jul 2026 ➔ Jun 2027
Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease
October 17, 2024
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=180 | Recruiting | Sponsor: ViiV Healthcare | N=60 ➔ 180
Enrollment change • Human Immunodeficiency Virus • Infectious Disease
September 20, 2024
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=60 | Recruiting | Sponsor: ViiV Healthcare | Trial primary completion date: Feb 2026 ➔ Oct 2026
Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease
May 31, 2024
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=60 | Recruiting | Sponsor: ViiV Healthcare | Trial completion date: Nov 2025 ➔ Nov 2027 | Trial primary completion date: Nov 2025 ➔ Feb 2026
Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease
December 15, 2023
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=60 | Recruiting | Sponsor: ViiV Healthcare | Trial completion date: May 2024 ➔ Sep 2025 | Trial primary completion date: Oct 2023 ➔ Sep 2025
Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease
July 06, 2022
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=60 | Recruiting | Sponsor: ViiV Healthcare | Not yet recruiting ➔ Recruiting
Enrollment open • Human Immunodeficiency Virus • Infectious Disease
June 14, 2022
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=60 | Not yet recruiting | Sponsor: ViiV Healthcare
New P1 trial • Human Immunodeficiency Virus • Infectious Disease
1 to 7
Of
7
Go to page
1